Mazonakis Michalis, Berris Theocharis, Varveris Charalambos, Lyraraki Efrossyni, Damilakis John
Department of Medical Physics, Faculty of Medicine, University of Crete, P. O. Box 2208, 71003 Iraklion, Crete, Greece.
Department of Radiotherapy and Oncology, University Hospital of Iraklion, 71110 Iraklion, Crete, Greece.
Med Phys. 2014 May;41(5):051702. doi: 10.1118/1.4870376.
The aims of this study were to (a) calculate the radiation dose to out-of-field organs from radiotherapy for stage I testicular seminoma and (b) estimate the associated radiogenic risks.
Monte Carlo methodology was employed to model radiation therapy with typical anteroposterior and posteroanterior para-aortic fields on an anthropomorphic phantom simulating an average adult. The radiation dose received by all main and remaining organs that defined by the ICRP publication 103 and excluded from the treatment volume was calculated. The effect of field dimensions on each organ dose was determined. Additional therapy simulations were generated by introducing shielding blocks to protect the kidneys from primary radiation. The gonadal dose was employed to assess the risk of heritable effects for irradiated male patients of reproductive potential. The lifetime attributable risks (LAR) of radiotherapy-induced cancer were estimated using gender- and organ-specific risk coefficients for patient ages of 20, 30, 40, and 50 years old. The risk values were compared with the respective nominal risks.
Para-aortic irradiation to 20 Gy resulted in out-of-field organ doses of 5.0-538.6 mGy. Blocked field treatment led to a dose change up to 28%. The mean organ dose variation by increasing or decreasing the applied field dimensions was 18.7% ± 3.9% and 20.8% ± 4.5%, respectively. The out-of-field photon doses increased the lifetime intrinsic risk of developing thyroid, lung, bladder, prostate, and esophageal cancer by (0.1-1.4)%, (0.4-1.1)%, (2.5-5.4)%, (0.2-0.4)%, and (6.4-9.2)%, respectively, depending upon the patient age at exposure and the field size employed. A low risk for heritable effects of less than 0.029% was found compared with the natural incidence of these defects.
Testicular cancer survivors are subjected to an increased risk for the induction of bladder and esophageal cancer following para-aortic radiotherapy. The probability for the appearance of any other malignant disease to out-of-field organs was slightly elevated in respect to the nominal cancer incidence rates.
本研究的目的是:(a) 计算 I 期睾丸精原细胞瘤放射治疗中射野外器官的辐射剂量,以及 (b) 估计相关的辐射致癌风险。
采用蒙特卡罗方法,在模拟平均成年人的人体模型上,对典型的前后位和后前位腹主动脉旁野放射治疗进行建模。计算了国际辐射防护委员会 (ICRP) 出版物 103 定义的、被排除在治疗体积之外的所有主要和其余器官所接受的辐射剂量。确定了野尺寸对每个器官剂量的影响。通过引入屏蔽块来保护肾脏免受原发射线照射,进行了额外的治疗模拟。采用性腺剂量评估有生殖潜力的受照男性患者的遗传效应风险。使用 20、30、40 和 50 岁患者的性别和器官特异性风险系数,估计放射治疗诱发癌症的终身归因风险 (LAR)。将风险值与各自的标称风险进行比较。
腹主动脉旁照射至 20 Gy 导致射野外器官剂量为 5.0 - 538.6 mGy。加屏蔽块的野治疗导致剂量变化高达 28%。增加或减少应用野尺寸时,平均器官剂量变化分别为 18.7% ± 3.9% 和 20.8% ± 4.5%。根据暴露时的患者年龄和所采用的野大小,射野外光子剂量分别使发生甲状腺癌、肺癌、膀胱癌、前列腺癌和食管癌的终身固有风险增加 (0.1 - 1.4)%、(0.4 - 1.1)%、(2.5 - 5.4)%、(0.2 - 0.4)% 和 (6.4 - 9.2)%。与这些缺陷的自然发生率相比,发现遗传效应的风险较低,低于 0.029%。
睾丸癌幸存者在接受腹主动脉旁放射治疗后,患膀胱癌和食管癌的风险增加。相对于标称癌症发病率,射野外器官出现任何其他恶性疾病的概率略有升高。